Healthcare & Biotech

SHERIDAN, WYOMING - November 13, 2025 - MEDICA 2025 is gearing up to become a defining stage for the convergence of artificial intelligence, robotics, genomics, and digital health. From November 17-20, the world's leading healthcare trade fair in Düsseldorf will transform Hall 12 into a "Future Tech Hotspot," where international experts, start-ups, and industry leaders will shape the next chapter of medical innovation through the redesigned MEDICA INNOVATION FORUM.

From AI to Digital Twins: Technologies Reshaping Clinical Practice

SHERIDAN, WYOMING - November 10, 2025 - Johnson & Johnson has secured a major regulatory milestone for its oncology portfolio, with the U.S. Food and Drug Administration granting approval for Darzalex Faspro in patients with high-risk smoldering multiple myeloma. The expansion marks the first-ever therapy authorized for this pre-malignant stage of the disease, reinforcing J&J's leadership in hematologic oncology and enabling earlier clinical intervention to delay disease progression.

A Landmark Step Toward Early Intervention in Myeloma

Darzalex Faspro's new indication targets adults with high-risk smoldering multiple myeloma-patients statistically more likely to develop active disease within two years of diagnosis. By offering the first approved option at this pre-symptomatic stage, J&J is advancing a proactive "disease interception" approach that could reshape treatment timelines for oncologists and hematology practices.

SHERIDAN, WYOMING - November 10, 2025 - Moderna's latest quarterly report signals cautious optimism for the biotech sector, as the company's cost-reduction campaign shows measurable progress in curbing financial losses. The mRNA innovator reported a $200 million net loss for the third quarter-its fourth consecutive decline-but markedly smaller than previous quarters. Executives emphasized that the company is regaining operational balance through disciplined expense management and diversification beyond COVID-19 vaccines.

Cost Discipline Accelerates Turnaround Momentum

After steep losses of $1 billion in the first quarter and $800 million in the second, Moderna's third-quarter results demonstrate its most significant improvement to date. The company's leadership attributes the recovery to a sweeping cost-cutting plan that has exceeded expectations.

SHERIDAN, WYOMING - November 10, 2025 - A pivotal decision at the Sixth Conference of the Parties (COP6) to the Minamata Convention on Mercury has extended the global phase-out date for dental amalgam from 2030 to 2034. The outcome represents a major win for oral and public health, driven by coordinated advocacy from the FDI World Dental Federation (FDI) and the International Association for Dental, Oral, and Craniofacial Research (IADR).

A Milestone for Equity and Patient-Centered Care

The new COP6 agreement establishes that the manufacture, import, and export of dental amalgam will cease globally by 2034. Crucially, it includes an exemption permitting its use "when its use is considered necessary by the dental practitioner based on the needs of the patient." This ensures clinicians can continue providing essential restorative care in cases where alternatives remain inaccessible or unsuitable-especially in low-resource settings.

SHERIDAN, WYOMING - November 10, 2025 - The FDI World Dental Federation has named three innovative projects from Nigeria, Kenya, and Tanzania as recipients of the 2025 World Dental Development Fund (WDDF), underscoring a strong commitment to equitable access to oral health care in low-resource settings. Each project demonstrates how community-based initiatives can integrate dental care into broader health and social development programs.

Integrating Oral Health Into Nutrition Programs in Nigeria

In Oyo State, Nigeria, the NOMALnutrition initiative is redefining community health delivery by embedding oral health care within existing nutrition programmes. Partnering with six organizations that already support vulnerable populations such as children living on the street and elderly rural residents, the project will reach approximately 500 people each month.

SHERIDAN, WYOMING - November 10, 2025 - Over the past five years, FDI World Dental Federation's Tobacco Cessation project has redefined the role of oral health professionals in combating one of the world's leading causes of preventable disease and death. By integrating evidence-based cessation strategies into dental practice, the initiative has empowered dentists and hygienists worldwide to help patients take meaningful steps toward quitting tobacco.

Building Global Capacity Through Education

Launched in 2020, the project established an ambitious goal: to embed tobacco cessation counseling directly into everyday dental care. FDI's interactive workshops-centered on the 5As (Ask, Advise, Assess, Assist, Arrange) and 5Rs (Relevance, Risks, Rewards, Roadblocks, Repetition)-equip participants with the communication tools and clinical confidence needed to address tobacco use during routine appointments.

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. has announced a significant leadership transition, positioning its executive team for continued strategic growth in the musculoskeletal technology sector. Effective July 18, 2025, Keith Pfeil assumed the role of President and Chief Executive Officer, succeeding Daniel Scavilla, who stepped down to pursue another opportunity. Additionally, Kyle Kline was appointed Senior Vice President and Chief Financial Officer.

Leadership Shifts Focused on Strategic Growth

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. has scheduled the announcement of its financial results for the second quarter ended June 30, 2025, for Thursday, August 7, 2025, after market close. The musculoskeletal technology leader will publish the earnings release on its investor relations website at www.investors.globusmedical.com.

Investor Call Scheduled for August 7

Following the earnings release, Globus Medical will host a teleconference with the investment community at 4:30 p.m. Eastern Time on the same day. The company offers multiple ways for stakeholders to join the event:

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. has announced the expansion of its Excelsius™ navigation capabilities with the introduction of DuraPro™, a next-generation oscillating system designed to enhance surgical precision while safeguarding delicate tissue. As part of the company’s Power Portfolio, DuraPro™ aims to optimize procedural workflows by combining advanced oscillating technology with integrated navigation.

Advancing the High-Speed Drill Market with Next-Generation Oscillation

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. (NYSE: GMED), a global leader in musculoskeletal solutions, today announced a significant strategic initiative with the authorization of a share repurchase program of up to $500 million of the company’s outstanding common stock. The move underscores Globus Medical’s confidence in its long-term business fundamentals and commitment to delivering sustained value for shareholders.

Strategic Response to Market Valuation Trends